Vivos Therapeutics, Inc. logo

Vivos Therapeutics, Inc. (VVOS) Q1 2026 Annual Earnings

VVOS·Reported May 20, 2026·After market close

Vivos Therapeutics, Inc. reported Q1 2026 revenue of $5.1M (+70.5% YoY), beat analyst consensus of $4.3M by $792.3K. Diluted EPS came in at $-0.52 (-15.6% YoY), missed the $-0.45 consensus by $0.07.

Revenue
$5.1Mbeat by $792.3K
Consensus: $4.3M
Diluted EPS
$-0.52missed by $0.07
Consensus: $-0.45
SEC

SEC Filings

Earnings release8-K not filed yet
Annual report10-K · 0001493152-26-016854

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Vivos Therapeutics, Inc.'s Q1 2026 earnings report.

Vivos Therapeutics, Inc. (VVOS) reported Q1 2026 earnings on May 20, 2026 after market close.

Vivos Therapeutics, Inc. reported revenue of $5.1M and diluted EPS of $-0.52 for Q1 2026.

Revenue beat the consensus estimate of $4.3M by $792.3K. EPS missed the consensus estimate of $-0.45 by $0.07.

Compared to the same quarter a year prior, revenue grew 70.5% from $3.0M a year earlier and diluted EPS declined 15.6% from $-0.45.

You can read the 10-K periodic report (0001493152-26-016854) directly on SEC EDGAR. The filing index links above go to sec.gov.